What question did this study set out to answer?

To measure the rate of decline and long-term persistence of anti-PRP antibodies up to 18 months of age in Gambian infants vaccinated with PRP-OMPC on two early infancy schedules.

January 1, 1993Annals of Tropical Paediatrics

Persistence of antibody at 18 months following vaccination of young Gambian infants with PRP-OMPCHaemophilus influenzaetype b conjugate vaccine

View Full Paper

Ask AI

Bookmark

Authors

KMKim MulhollandUniversity of London JTJim ToddCentre for Human Genetics MRMary Hannah RoweMRC Unit the Gambia

Discussion

Member takes

Implication

Comparative study reveals declining anti-PRP antibodies by 18 months in vaccinated infants, indicating that a late booster dose is necessary for lasting protection.

Key Points

To measure the rate of decline and long-term persistence of anti-PRP antibodies up to 18 months of age in Gambian infants vaccinated with PRP-OMPC on two early infancy schedules.
Followed two cohorts of Gambian infants immunized with PRP-OMPC at either 1 and 3 months of age (n = 70) or 2 and 4 months of age (n = 54).
Assayed serum anti-PRP geometric mean titres at post-vaccination intervals and at 18 months of age to determine antibody decline and half-life.
Geometric mean titres fell from 1.32 µg/ml at 4 months to 0.44 µg/ml at 18 months in the 1- and 3-month cohort (n = 70), and from 1.18 µg/ml at 5 months to 0.46 µg/ml at 18 months in the 2- and 4-month cohort (n = 54).
The proportion of children with protective antibody levels >1.0 µg/ml declined from 54% post-dose two to 27% at 18 months, and levels >0.15 µg/ml decreased from 82% to 60%, showing no significant differences between the two schedules.
The estimated half-life of anti-PRP antibodies was approximately 100 days in children without evidence of environmental boosting across both groups.

Cite This Study

Mulholland et al. (1993) studied this question.

synapsesocial.com/papers/6a6f7eb38031ec7bb1dbc6bb https://doi.org/10.1080/02724936.1993.11747639

View Full Paper

Ask AI

Bookmark

Implication

Comparative study reveals declining anti-PRP antibodies by 18 months in vaccinated infants, indicating that a late booster dose is necessary for lasting protection.

Persistence of antibody at 18 months following vaccination of young Gambian infants with PRP-OMPCHaemophilus influenzaetype b conjugate vaccine

Discussion

Member takes

Implication

Key Points

Cite This Study

Persistence of antibody at 18 months following vaccination of young Gambian infants with PRP-OMPCHaemophilus influenzaetype b conjugate vaccine

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider